Fig. 2: Immunogenicity of Delta prototype mRNA-VLP vaccine in naive mice. | npj Vaccines

Fig. 2: Immunogenicity of Delta prototype mRNA-VLP vaccine in naive mice.

From: Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2

Fig. 2

A Groups of naive BALB/c mice (n = 4–6 /group) were administered 1.0 μg of LNP-formulated mRNA vaccine (mRNA-native Delta or mRNA-VLP Delta) or PBS control intramuscularly on study days 1 and 28. Fourteen days following the second dose (study day 42), sera were collected and pseudovirus-based neutralization assays performed using a panel of SARS-CoV-2 pseudoviruses (pV) as indicated. B Phylogenetic tree of SARS-CoV-2 spike sequences. C Day 42 serum anti-SARS-CoV-2 neutralization antibody titers. The geometric mean titer (GMT) ± geometric standard deviation is shown with indicated p value comparing the mRNA-native and mRNA-VLP responses for each tested pV by the Wilcoxon–Mann–Whitney test; the dotted horizontal line indicates the assay lower limit of detection (LLD). Ab antibody, D614G ancestral D614G spike, ID50 half-maximal inhibitory dilution, LNP lipid nanoparticle, native full-length Delta spike protein containing the S2P pre-fusion spike stabilization mutations, ns not significant, PBS phosphate-buffered saline, pV pseudovirus, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2, VLP virus-like particle.

Back to article page